購(gòu)物車(chē) 
-
卡達(dá)唑胺
- names：
Cadazolid
- CAS號(hào)：
1025097-10-2
MDL Number： - MF(分子式)： C29H29F2N3O8 MW(分子量)： 585.55
- EINECS: Reaxys Number:
- Pubchem ID:44242317 Brand:BIOFOUNT
卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)是一種新的惡唑烷酮類(lèi)抗生素，對(duì)艱難梭菌具有有效的活性。
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000084-5mg | 5mg | 97.44% | ￥ 1072.50 | ￥ 1072.50 | 2-3天 | ￥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)
| 中文別名 | 卡達(dá)唑胺(1025097-10-2);卡達(dá)唑利德;卡達(dá)唑烷; |
| 英文別名 | Cadazolid(1025097-10-2);Cadazolid;ACT 179811;ACT179811;ACT-179811;ACT-179811; ACT 179811; ACT179811; CADAZOLID.;Cadazolid (ACT-179811);CS-2475; |
| CAS號(hào) | 1025097-10-2 |
| Inchi | InChI=1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)/t18-/m1/s1 |
| InchiKey | XWFCFMXQTBGXQW-GOSISDBHSA-N |
| 分子式 Formula | C29H29F2N3O8 |
| 分子量 Molecular Weight | 585.55 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 150 mg/mL(256.17 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C , 存放在陰涼干燥處,3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過(guò)程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類(lèi)存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:卡達(dá)唑胺試劑,卡達(dá)唑胺雜質(zhì),卡達(dá)唑胺中間體,卡達(dá)唑胺合成,卡達(dá)唑胺溶解度,卡達(dá)唑胺旋光度,卡達(dá)唑胺密度,卡達(dá)唑胺閃點(diǎn),卡達(dá)唑胺結(jié)構(gòu)式,卡達(dá)唑胺購(gòu)買(mǎi)，
| 產(chǎn)品說(shuō)明 | 卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)是一種有效的新的惡唑烷酮類(lèi)抗生素，對(duì)Clostridium difficile具有有效的活性 |
| Introduction | 卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)is a new oxazolidinone antibiotic with potent activity againstClostridium difficile. |
| Application1 | 卡達(dá)唑胺，也稱為ACT-179811，是一種新的氟喹諾酮惡唑烷酮抗生素，對(duì)艱難梭菌具有有效活性。 |
| Application2 | |
| Application3 |
卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)藥理學(xué)：
卡達(dá)唑胺是惡唑烷酮類(lèi)抗生素，對(duì)革蘭氏陽(yáng)性細(xì)菌（包括艱難梭菌）具有活性。盡管尚未完全闡明卡達(dá)唑利德發(fā)揮作用的確切作用方式，但在給藥時(shí)，該藥物抑制細(xì)菌蛋白質(zhì)的合成并導(dǎo)致細(xì)菌細(xì)胞死亡。 卡達(dá)唑利德已用于研究艱難梭菌感染治療的試驗(yàn)中。
卡達(dá)唑胺是惡唑烷酮類(lèi)抗生素，對(duì)革蘭氏陽(yáng)性細(xì)菌（包括艱難梭菌）具有活性。盡管尚未完全闡明卡達(dá)唑利德發(fā)揮作用的確切作用方式，但在給藥時(shí)，該藥物抑制細(xì)菌蛋白質(zhì)的合成并導(dǎo)致細(xì)菌細(xì)胞死亡。 卡達(dá)唑利德已用于研究艱難梭菌感染治療的試驗(yàn)中。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過(guò)程中防止吸入、食入，做好安全防護(hù) |
| Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral dos |
| Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69 |
| Cadazolid for the treatment of Clostridium difficile PMID 28286992; Expert opinion on investigational drugs 2017 Apr; 26(4):509-514 (Review Article) Name matches: surotomycin cadazolid |
| Novel Antimicrobials for the Treatment of Clostridium difficile Infection PMID 29713630; Frontiers in medicine 2018; 5(?):96 (Review Article) Name matches: surotomycin cadazolid |
| Management of adult Clostridium difficile digestive contaminations: a literature review PMID 30498879; European journal of clinical microbiology & infectious diseases : official publication of the Eur |
卡達(dá)唑胺(1025097-10-2,ACT-179811,Cadazolid)參考文獻(xiàn)：
1.Novel Antimicrobials for the Treatment of
Petrosillo N;Granata G;Cataldo MA Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.
The current picture of ;Clostridium difficile; infection (CDI) is alarming with a mortality rate ranging between 3% and 15% and a CDI recurrence rate ranging from 12% to 40%. Despite the great efforts made over the past 10 years to face the CDI burden, there are still gray areas in our knowledge on CDI management. The traditional anti-CDI antimicrobials are not always adequate in addressing the current needs in CDI management. The aim of our review is to give an update on novel antimicrobials for the treatment of CDI, considering the currently available evidences on their efficacy, safety, molecular mechanism of action, and their probability to be successfully introduced into the clinical practice in the near future. We identified, through a PubMed search, 16 novel antimicrobial molecules under study for CDI treatment: cadazolid, surotomycin, ridinilazole, LFF571, ramoplanin, CRS3123, fusidic acid, nitazoxanide, rifampin, rifaximin, tigecycline, auranofin, NVB302, thuricin CD, lacticin 3147, and acyldepsipeptide antimicrobials. In comparison with the traditional anti-CDI antimicrobial treatment, some of the novel antimicrobials reviewed in this study offer several advantages, i.e., the favorable pharmacokinetic and pharmacodynamic profile, the narrow-spectrum activity against CD that implicates a low impact on the gut microbiota composition, the inhibitory activity on CD sporulation and toxins production.
2.[New antibacterial agents on the market and in the pipeline].
Kern WV Internist (Berl). 2015 Nov;56(11):1255-63.
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of these new developments have been in conventional antibacterial classes. New drugs among the beta-lactam agents are methicillin-resistant Staphylococcus aureus (MRSA) active cephalosporins (ceftaroline and ceftobiprole) and new combinations of beta-lactam with beta-lactamase inhibitors (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam and meropenem/RPX7009). New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin). New agents in a very early developmental phase are FabI inhibitors, endolysines, peptidomimetics, lipid A inhibitors, methionyl-tRNA synthetase inhibitors and teixobactin.
3.[Treatment of acute and recurrent Clostridium difficile infections : What is new?]
von Braun A;Lübbert C Internist (Berl). 2018 May;59(5):505-513. doi: 10.1007/s00108-018-0401-x.
The incidence of clostridium difficile infections (CDI) remains on a high level globally. In Germany, the number of severe or even lethal cases continues to increase. The main risk factor for the development of CDI is exposure to broad spectrum antibiotics, which disturb the physiological microbiome and therefore enable colonization with C. difficile. According to the updated US and European guidelines, orally administered vancomycin is the treatment of choice. Fidaxomicin is as effective as vancomycin but has the advantage of a lower rate of recurrence. Furthermore, recent clinical studies were able to demonstrate that significantly fewer recurrences occurred in patients who additionally received the monoclonal antibody bezlotoxumab. In recent years, several new antibiotics with narrow-spectrum acitivity and low intestinal resorption have been developed for the treatment of CDI, including surotomycin, cadazolid, and ridinilazol. Novel toxoid vaccines are expected to become an efficacious tool in the prevention of CDI; however, pivotal clinical trials have so far not been completed.
1.Novel Antimicrobials for the Treatment of
Petrosillo N;Granata G;Cataldo MA Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.
The current picture of ;Clostridium difficile; infection (CDI) is alarming with a mortality rate ranging between 3% and 15% and a CDI recurrence rate ranging from 12% to 40%. Despite the great efforts made over the past 10 years to face the CDI burden, there are still gray areas in our knowledge on CDI management. The traditional anti-CDI antimicrobials are not always adequate in addressing the current needs in CDI management. The aim of our review is to give an update on novel antimicrobials for the treatment of CDI, considering the currently available evidences on their efficacy, safety, molecular mechanism of action, and their probability to be successfully introduced into the clinical practice in the near future. We identified, through a PubMed search, 16 novel antimicrobial molecules under study for CDI treatment: cadazolid, surotomycin, ridinilazole, LFF571, ramoplanin, CRS3123, fusidic acid, nitazoxanide, rifampin, rifaximin, tigecycline, auranofin, NVB302, thuricin CD, lacticin 3147, and acyldepsipeptide antimicrobials. In comparison with the traditional anti-CDI antimicrobial treatment, some of the novel antimicrobials reviewed in this study offer several advantages, i.e., the favorable pharmacokinetic and pharmacodynamic profile, the narrow-spectrum activity against CD that implicates a low impact on the gut microbiota composition, the inhibitory activity on CD sporulation and toxins production.
2.[New antibacterial agents on the market and in the pipeline].
Kern WV Internist (Berl). 2015 Nov;56(11):1255-63.
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of these new developments have been in conventional antibacterial classes. New drugs among the beta-lactam agents are methicillin-resistant Staphylococcus aureus (MRSA) active cephalosporins (ceftaroline and ceftobiprole) and new combinations of beta-lactam with beta-lactamase inhibitors (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam and meropenem/RPX7009). New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin). New agents in a very early developmental phase are FabI inhibitors, endolysines, peptidomimetics, lipid A inhibitors, methionyl-tRNA synthetase inhibitors and teixobactin.
3.[Treatment of acute and recurrent Clostridium difficile infections : What is new?]
von Braun A;Lübbert C Internist (Berl). 2018 May;59(5):505-513. doi: 10.1007/s00108-018-0401-x.
The incidence of clostridium difficile infections (CDI) remains on a high level globally. In Germany, the number of severe or even lethal cases continues to increase. The main risk factor for the development of CDI is exposure to broad spectrum antibiotics, which disturb the physiological microbiome and therefore enable colonization with C. difficile. According to the updated US and European guidelines, orally administered vancomycin is the treatment of choice. Fidaxomicin is as effective as vancomycin but has the advantage of a lower rate of recurrence. Furthermore, recent clinical studies were able to demonstrate that significantly fewer recurrences occurred in patients who additionally received the monoclonal antibody bezlotoxumab. In recent years, several new antibiotics with narrow-spectrum acitivity and low intestinal resorption have been developed for the treatment of CDI, including surotomycin, cadazolid, and ridinilazol. Novel toxoid vaccines are expected to become an efficacious tool in the prevention of CDI; however, pivotal clinical trials have so far not been completed.
對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開(kāi)
SDS 1.0 英文
展開(kāi)
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
脂.png)
chelex 100樹(shù)脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹(shù)脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽(yáng)離子的偏好。它對(duì)二價(jià)...
2025/11/4 14:22:46
9月開(kāi)學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái)，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
材料.jpg)
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說(shuō)明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
